Is EDSA or NBP more profitable?

I-Mab's return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -286.52% -75.36% I-Mab N/A N/A N/A

Does the media refer more to KROS or EDSA?

In the previous week, Keros Therapeutics had 7 more articles in the media than Edesa Biotech. MarketBeat recorded 8 mentions for Keros Therapeutics and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.00 beat Keros Therapeutics' score of -0.31 indicating that Edesa Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Edesa Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, GLSI or EDSA?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is GLSI or EDSA more profitable?

Edesa Biotech's return on equity of -286.52% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -941.15% -368.53% Edesa Biotech N/A -286.52% -75.36%

Does the media prefer GLSI or EDSA?

In the previous week, Greenwich LifeSciences had 8 more articles in the media than Edesa Biotech. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 1 mentions for Edesa Biotech. Greenwich LifeSciences' average media sentiment score of 1.49 beat Edesa Biotech's score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenwich LifeSciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edesa Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RNA or EDSA?

In the previous week, Avidity Biosciences and Avidity Biosciences both had 1 articles in the media. Avidity Biosciences' average media sentiment score of 1.02 beat Edesa Biotech's score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edesa Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, NERV or EDSA?

Edesa Biotech is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is NERV or EDSA more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -32.63% Edesa Biotech N/A -286.52% -75.36%

Does the media refer more to NERV or EDSA?

In the previous week, Minerva Neurosciences had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for Minerva Neurosciences and 1 mentions for Edesa Biotech. Minerva Neurosciences' average media sentiment score of 1.75 beat Edesa Biotech's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Edesa Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Edesa Biotech (EDSA) Competitors

$5.23 +0.12 (+2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$5.21 -0.02 (-0.31%)

As of 07:38 PM Eastern

Compare

EDSA vs. NBP, KROS, GLSI, RNA, and NERV

Should you buy Edesa Biotech stock or one of its competitors? MarketBeat compares Edesa Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Edesa Biotech include I-Mab (NBP), Keros Therapeutics (KROS), Greenwich LifeSciences (GLSI), Avidity Biosciences (RNA), and Minerva Neurosciences (NERV).

How does Edesa Biotech compare to I-Mab?

Edesa Biotech (NASDAQ:EDSA) and I-Mab (NASDAQ:NBP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Edesa Biotech has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, I-Mab has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

Edesa Biotech presently has a consensus target price of $5.00, suggesting a potential downside of 4.40%. I-Mab has a consensus target price of $9.00, suggesting a potential upside of 459.01%. Given I-Mab's higher possible upside, analysts plainly believe I-Mab is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

I-Mab's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
I-Mab	N/A	N/A	N/A

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by insiders. Comparatively, 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Edesa Biotech had 1 more articles in the media than I-Mab. MarketBeat recorded 1 mentions for Edesa Biotech and 0 mentions for I-Mab. Edesa Biotech's average media sentiment score of 0.00 equaled I-Mab'saverage media sentiment score.

Company	Overall Sentiment
Edesa Biotech	Neutral
I-Mab	Neutral

Edesa Biotech has higher earnings, but lower revenue than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
I-Mab	$3.89M	47.87	-$46.27M	-$0.36	N/A

Summary

I-Mab beats Edesa Biotech on 7 of the 13 factors compared between the two stocks.

How does Edesa Biotech compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Keros Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Keros Therapeutics has higher revenue and earnings than Edesa Biotech. Edesa Biotech is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.82	$87.01M	-$3.01	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Keros Therapeutics currently has a consensus target price of $20.40, suggesting a potential upside of 101.78%. Edesa Biotech has a consensus target price of $5.00, suggesting a potential downside of 4.40%. Given Keros Therapeutics' higher probable upside, equities analysts clearly believe Keros Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Edesa Biotech has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -17.04% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
Edesa Biotech	N/A	-286.52%	-75.36%

In the previous week, Keros Therapeutics had 7 more articles in the media than Edesa Biotech. MarketBeat recorded 8 mentions for Keros Therapeutics and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.00 beat Keros Therapeutics' score of -0.31 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Edesa Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Keros Therapeutics beats Edesa Biotech on 9 of the 16 factors compared between the two stocks.

How does Edesa Biotech compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Edesa Biotech's return on equity of -286.52% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
Edesa Biotech	N/A	-286.52%	-75.36%

Greenwich LifeSciences presently has a consensus price target of $57.00, suggesting a potential upside of 320.97%. Edesa Biotech has a consensus price target of $5.00, suggesting a potential downside of 4.40%. Given Greenwich LifeSciences' higher probable upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Greenwich LifeSciences had 8 more articles in the media than Edesa Biotech. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 1 mentions for Edesa Biotech. Greenwich LifeSciences' average media sentiment score of 1.49 beat Edesa Biotech's score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edesa Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Greenwich LifeSciences has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Summary

Edesa Biotech beats Greenwich LifeSciences on 8 of the 14 factors compared between the two stocks.

How does Edesa Biotech compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

5.5% of Edesa Biotech shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Avidity Biosciences has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Edesa Biotech has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.28	-$322.30M	-$0.97	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Avidity Biosciences currently has a consensus target price of $67.60, indicating a potential upside of 496.65%. Edesa Biotech has a consensus target price of $5.00, indicating a potential downside of 4.40%. Given Avidity Biosciences' higher possible upside, equities research analysts plainly believe Avidity Biosciences is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.28
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Edesa Biotech has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Edesa Biotech	N/A	-286.52%	-75.36%

In the previous week, Avidity Biosciences and Avidity Biosciences both had 1 articles in the media. Avidity Biosciences' average media sentiment score of 1.02 beat Edesa Biotech's score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edesa Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avidity Biosciences beats Edesa Biotech on 8 of the 14 factors compared between the two stocks.

How does Edesa Biotech compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Minerva Neurosciences presently has a consensus price target of $10.50, indicating a potential upside of 164.48%. Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 4.40%. Given Minerva Neurosciences' higher possible upside, research analysts plainly believe Minerva Neurosciences is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Minerva Neurosciences has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Minerva Neurosciences' return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Edesa Biotech	N/A	-286.52%	-75.36%

In the previous week, Minerva Neurosciences had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for Minerva Neurosciences and 1 mentions for Edesa Biotech. Minerva Neurosciences' average media sentiment score of 1.75 beat Edesa Biotech's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Edesa Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edesa Biotech is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Summary

Minerva Neurosciences beats Edesa Biotech on 7 of the 13 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDSA vs. The Competition

Export

Metric	Edesa Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$49.23M	$3.55B	$6.86B	$12.45B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-3.90	7.29	280.72	24.99
Price / Sales	N/A	1,264.07	588.04	90.94
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	11.62	16.89	11.02	6.21
Net Income	-$7.19M	-$12.54M	$3.48B	$347.49M
7 Day Performance	-2.24%	-0.63%	0.56%	0.89%
1 Month Performance	-30.27%	-7.41%	-4.14%	-3.60%
1 Year Performance	144.39%	49.17%	63.23%	20.46%

Edesa Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDSA Edesa Biotech	0.863 of 5 stars	$5.23 +2.3%	$5.00 -4.4%	+138.8%	$49.23M	N/A	N/A	20	News Coverage
NBP I-Mab	1.6802 of 5 stars	$1.75 -1.7%	$9.00 +414.3%	N/A	$205.85M	$3.89M	N/A	380
KROS Keros Therapeutics	2.3999 of 5 stars	$10.07 -1.4%	$20.40 +102.6%	-29.7%	$202.07M	$244.06M	N/A	100	News Coverage Earnings Report Upcoming Earnings
GLSI Greenwich LifeSciences	3.0798 of 5 stars	$13.45 +0.1%	$57.00 +323.8%	+21.7%	$197.27M	N/A	N/A	3	Positive News
RNA Avidity Biosciences	2.4579 of 5 stars	$11.49 -0.7%	$67.60 +488.3%	-68.4%	$196.55M	$36.68M	N/A	190

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDSA) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edesa Biotech (EDSA) Competitors

EDSA vs. NBP, KROS, GLSI, RNA, and NERV

How does Edesa Biotech compare to I-Mab?

Summary

How does Edesa Biotech compare to Keros Therapeutics?

Summary

How does Edesa Biotech compare to Greenwich LifeSciences?

Summary

How does Edesa Biotech compare to Avidity Biosciences?

Summary

How does Edesa Biotech compare to Minerva Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edesa Biotech (EDSA) Competitors

EDSA vs. NBP, KROS, GLSI, RNA, and NERV

How does Edesa Biotech compare to I-Mab?

Which has more volatility and risk, EDSA or NBP?

Do analysts rate EDSA or NBP?

Is EDSA or NBP more profitable?

Do institutionals & insiders hold more shares of EDSA or NBP?

Does the media favor EDSA or NBP?

Which has preferable valuation and earnings, EDSA or NBP?

Summary

How does Edesa Biotech compare to Keros Therapeutics?

Which has more volatility and risk, KROS or EDSA?

Which has better earnings and valuation, KROS or EDSA?

Do analysts prefer KROS or EDSA?

Do institutionals and insiders have more ownership in KROS or EDSA?

Is KROS or EDSA more profitable?

Does the media refer more to KROS or EDSA?

Summary

How does Edesa Biotech compare to Greenwich LifeSciences?

Which has higher valuation and earnings, GLSI or EDSA?

Do institutionals & insiders have more ownership in GLSI or EDSA?

Is GLSI or EDSA more profitable?

Do analysts prefer GLSI or EDSA?

Does the media prefer GLSI or EDSA?

Which has more risk & volatility, GLSI or EDSA?

Summary

How does Edesa Biotech compare to Avidity Biosciences?

Do insiders & institutionals have more ownership in RNA or EDSA?

Which has more risk & volatility, RNA or EDSA?

Which has preferable valuation & earnings, RNA or EDSA?

Do analysts recommend RNA or EDSA?

Is RNA or EDSA more profitable?

Does the media refer more to RNA or EDSA?

Summary

How does Edesa Biotech compare to Minerva Neurosciences?

Do analysts recommend NERV or EDSA?

Do insiders and institutionals have more ownership in NERV or EDSA?

Which has more volatility & risk, NERV or EDSA?

Is NERV or EDSA more profitable?

Does the media refer more to NERV or EDSA?

Which has stronger valuation and earnings, NERV or EDSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools